TNFRSF8 and peripheral T-cell lymphoma, not otherwise specified: The CD30-specific antibody drug conjugate brentuximab vedotin treatment is an important immunotherapy option at present, with promising anti-tumor activity and manageable toxicity in cHL and CD30-positive peripheral T-cell lymphoma (10), but the long-term disease control capacity really needed to be improved.